DOP2023000009A - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo - Google Patents
Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-iloInfo
- Publication number
- DOP2023000009A DOP2023000009A DO2023000009A DO2023000009A DOP2023000009A DO P2023000009 A DOP2023000009 A DO P2023000009A DO 2023000009 A DO2023000009 A DO 2023000009A DO 2023000009 A DO2023000009 A DO 2023000009A DO P2023000009 A DOP2023000009 A DO P2023000009A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compound
- ylo
- oxadiazole
- formulation
- methyl
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000009A true DOP2023000009A (es) | 2023-02-15 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000009A DOP2023000009A (es) | 2020-07-23 | 2023-01-20 | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (https=) |
| EP (1) | EP4185291B1 (https=) |
| JP (1) | JP2023535034A (https=) |
| KR (1) | KR20230043905A (https=) |
| CN (1) | CN116323604A (https=) |
| AR (1) | AR123031A1 (https=) |
| AU (1) | AU2021312894B2 (https=) |
| BR (1) | BR112023000975A2 (https=) |
| CA (1) | CA3186808A1 (https=) |
| CL (1) | CL2023000194A1 (https=) |
| CO (1) | CO2023000594A2 (https=) |
| DO (1) | DOP2023000009A (https=) |
| EC (1) | ECSP23005057A (https=) |
| ES (1) | ES3039536T3 (https=) |
| IL (1) | IL300023A (https=) |
| JO (1) | JOP20230018A1 (https=) |
| MX (1) | MX2023000993A (https=) |
| PE (1) | PE20231031A1 (https=) |
| PH (1) | PH12023550177A1 (https=) |
| TW (1) | TW202220650A (https=) |
| WO (1) | WO2022020663A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| CA3107788A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185291B1 (en) | 2025-07-09 |
| AU2021312894B2 (en) | 2025-09-11 |
| WO2022020663A1 (en) | 2022-01-27 |
| MX2023000993A (es) | 2023-03-01 |
| CO2023000594A2 (es) | 2023-01-26 |
| PE20231031A1 (es) | 2023-07-10 |
| CL2023000194A1 (es) | 2023-07-21 |
| CN116323604A (zh) | 2023-06-23 |
| ECSP23005057A (es) | 2023-02-28 |
| JP2023535034A (ja) | 2023-08-15 |
| EP4185291A1 (en) | 2023-05-31 |
| CA3186808A1 (en) | 2022-01-27 |
| IL300023A (en) | 2023-03-01 |
| TW202220650A (zh) | 2022-06-01 |
| AR123031A1 (es) | 2022-10-26 |
| KR20230043905A (ko) | 2023-03-31 |
| EP4185291C0 (en) | 2025-07-09 |
| BR112023000975A2 (pt) | 2023-02-07 |
| JOP20230018A1 (ar) | 2023-01-23 |
| PH12023550177A1 (en) | 2024-03-18 |
| US20230338349A1 (en) | 2023-10-26 |
| ES3039536T3 (en) | 2025-10-22 |
| AU2021312894A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000167A1 (es) | Péptidos funcionalizados como agentes antivirales | |
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| MX2020007633A (es) | Péptidos macrocíclicos contra acinetobacter baumannii. | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
| MX2023005462A (es) | Compuestos macrociclicos y metodos para usarlos. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| PE20241327A1 (es) | Tratamiento de trastornos hepaticos con un agonista del thr-beta | |
| ECSP23017158A (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| ECSP23005057A (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2022005503A (es) | Composiciones farmaceuticas de apixaban de desintegracion oral. | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| DOP2024000018A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| PE20240241A1 (es) | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo |